

pct/09885247

Welcome to STN International! Enter x:x

LOGINID:sssptaul25txc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS	4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS	5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS	6	Mar 08	Gene Names now available in BIOSIS
NEWS	7	Mar 22	TOXLIT no longer available
NEWS	8	Mar 22	TRCTHERMO no longer available
NEWS	9	Mar 28	US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL
NEWS	10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS	11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS	12	Apr 08	"Ask CAS" for self-help around the clock
NEWS	13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	14	Apr 09	ZDB will be removed from STN
NEWS	15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	19	Jun 03	New e-mail delivery for search results now available
NEWS	20	Jun 10	MEDLINE Reload
NEWS	21	Jun 10	PCTFULL has been reloaded
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:33:02 ON 01 JUL 2002

pct/09885247

=> FILE REGISTRY
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:33:10 ON 01 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 28 JUN 2002 HIGHEST RN 435268-39-6
DICTIONARY FILE UPDATES: 28 JUN 2002 HIGHEST RN 435268-39-6

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> S RALOXIFENE
L1 19 RALOXIFENE

=> S RALOXIFENE/CN
L2 1 RALOXIFENE/CN

=> D L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 84449-90-1 REGISTRY
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-{2-(1-piperidinyl)ethoxy}phenyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Keoxifene
CN LY 139481
CN **Raloxifene**
CN [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone
FS 3D CONCORD
MF C28 H27 N O4 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CIN, CSCHM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE,
TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

pct/09885247



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

610 REFERENCES IN FILE CA (1967 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
614 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> FILE USPATFULL
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.34	10.55

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 09:34:04 ON 01 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 Jun 2002 (20020627/PD)
FILE LAST UPDATED: 27 Jun 2002 (20020627/ED)
HIGHEST GRANTED PATENT NUMBER: US6412112
HIGHEST APPLICATION PUBLICATION NUMBER: US2002083506
CA INDEXING IS CURRENT THROUGH 27 Jun 2002 (20020627/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 Jun 2002 (20020627/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> S RALOXIFENE AND ATHERIOSCLEROSIS
496 RALOXIFENE
21 ATHERIOSCLEROSIS

pct/09885247

L3 0 RALOXIFENE AND ATHERIOSCLEROSIS

=> S RALOXIFENE AND ATHRIOSCLEROSIS

496 RALOXIFENE

0 ATHRIOSCLEROSIS

L4 0 RALOXIFENE AND ATHRIOSCLEROSIS

=> S RALOXIFENE AND VASCULAR SMOOTH MUSCLE

496 RALOXIFENE

36248 VASCULAR

331712 SMOOTH

52376 MUSCLE

2863 VASCULAR SMOOTH MUSCLE

(VASCULAR(W) SMOOTH(W) MUSCLE)

L5 42 RALOXIFENE AND VASCULAR SMOOTH MUSCLE

=> S L5 AND PD<1996

2009159 PD<1996

(PD<19960000)

L6 2 L5 AND PD<1996

=> D L6 1-2

L6 ANSWER 1 OF 2 USPATFULL

AN 95:97021 USPATFULL

TI Methods for inhibiting **vascular smooth muscle** cell proliferation and restinosis

IN Cullinan, George J., Trafalgar, IN, United States

Singh, Jai P., Carmel, IN, United States

Wood, Dan L., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5462937 19951031 <--

AI US 1995-422286 19950414 (8)

RLI Division of Ser. No. US 1993-138296, filed on 15 Oct 1993

DT Utility

FS Granted

LN.CNT 446

INCL INCLM: 514/212.000

NCL NCLM: 514/212.010

IC [6]

ICM: A61K031-55

EXF 514/212

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPATFULL

AN 95:90537 USPATFULL

TI Methods for inhibiting **vascular smooth muscle** cell proliferation and restinosis

IN Cullinan, George J., Trafalgar, IN, United States

Singh, Jai P., Carmel, IN, United States

Wood, Dan L., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5457113 19951010 <--

AI US 1993-138296 19931015 (8)

DT Utility

FS Granted

LN.CNT 437

INCL INCLM: 514/319.000

pct/09885247

INCLS: 514/324.000
NCL NCLM: 514/319.000
NCLS: 514/324.000
IC [6]
ICM: A61K031-445
EXF 514/324; 514/325; 514/319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> D L6 KWIC 2

L6 ANSWER 2 OF 2 USPATFULL
TI Methods for inhibiting **vascular smooth muscle** cell proliferation and restinosis
PI US 5457113 19951010 <--
AB Methods of inhibiting **vascular smooth muscle** cell proliferation and vascular restinosis comprising administering to a human or other mammal in need of treatment an effective amount. . .
SUMM . . . by smooth muscle cells and macrophages contribute significantly to the pathogenesis of the disease. The excessive proliferation and migration of **vascular smooth muscle** cells may be the primary mechanism to the reocclusion of coronary arteries following PTCA, atherectomy, laser angioplasty and arterial bypass. .
DETD Examples of specific capsule formulations of the compound of formula 1 wherein the compound is **raloxifene**, include those shown below:

Ingredient	Quantity (mg/capsule)
Formulation 2: Raloxifene capsule	
Raloxifene	1
Starch, NF	112
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7
Formulation 3: Raloxifene capsule	
Raloxifene	5
Starch, NF	108
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7
Formulation 4: Raloxifene capsule	
Raloxifene	10
Starch, NF	103
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7
Formulation 5: Raloxifene capsule	
Raloxifene	50
Starch, NF	150
Starch flowable powder	397
Silicone fluid 350 centistokes	3.0

CLM What is claimed is:

pct/09885247

1. A method of inhibiting **vascular smooth muscle** cell proliferation comprising administering to a human or other mammal in need of treatment an effective amount of a compound. .